Impact of Fluorescence-Guided Resection and Chemoradiotherapy on the Systemic Immune Response in Glioblastoma: A Kinetic Analysis of Immune Biomarkers.

Inclusion Criteria: * Patient male or female ≥18 years * General status (WHO) of Performance status 0, 1 or 2 * Probable glioblastoma according to clinical and radiological criteria, * whose surgical indication was given in Multidisciplinary consultation meeting (RCP) of neurooncology, * Decision to treat the patient as part of the Clinical trial also taken in neuro-oncology RCP ("Multidisciplinary consultation meeting") * Patient operable on the basis of absence of cardiopulmonary disease history; a complete medical check-up sufficient to insure a post-operative state with normal daily life * Clinical neuro-oncological monitoring and long-term MRI scheduled at the hospital CHRU of Lille, center of reference of the region * Patient able to understand and sign voluntarily Informed consent * Patient able to adhere to the visit's calendar of the study and other imperatives of the protocol * Women of child-bearing potential should benefit of an effective contraception * For patients receiving hepatotoxic therapy in the long term, this treatment must be suspended during the 24h after taking 5-ALA * Patient assigned to an health insurance Exclusion Criteria: * Contraindications to 5-ALA (Gliolan®) * Porphyria * Taking photosensitizer treatment * Severe renal or hepatic impairment * Bilirubin\> 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)\> 2.5 x Maximum rates * Creatinine clearance \<30 mL / min; * Non-compliance with the rules of prevention o…